Following a $540 million IPO in May, Acelyrin’s lead candidate izokibep failed to meet the primary endpoint in a Phase IIb/III study of patients with the chronic inflammatory skin condition.
Featured Posts
How cognitive computing has evolved RWD use in drug development - Real-world data (RWD) improves health care – especially patient safety. The data enhances signal detection and management to identify and evaluate potential safety concerns. While it offers many advantages over traditional data sources for pharmacovigilance, simply having data is not enough. For optimal utility, healthcare entities must use effective data management tools.
Navigating the challenges of patient support in rare and orphan diseases - The pharma industry is facing an opportunity to overcome rare and orphan disease patient resistance and build long-term relationships through support programs specifically designed to best serve these populations and improve patient outcomes.
Moderna said the companies would use Immatics’ drug discovery platform to develop mRNA-based cancer vaccines, and also study its own cancer vaccine for use in combination with Immatics’ cancer therapy IMA203.
The California pharma is building up to its first-ever approval with promising late-stage data for its once-daily investigational acromegaly pill paltusotine, an alternative to the injectable standard of care.
Seeking to deepen its neurology and rare disease pipelines, AstraZeneca’s Alexion has joined forces with Verge Genomics to leverage its artificial intelligence platform in drug discovery and development.
To build its ophthalmology portfolio, Japan’s Otsuka Pharmaceuticals has teamed with RNA editing biotech Shape Therapeutics to develop adeno-associated virus gene therapies for ocular diseases.
The companies have started a collaboration worth up to $3.4 billion to develop a portfolio of degrader-antibody conjugates, a potentially new class of antibodies that selectively kill cancer cells.
Alnylam Pharmaceuticals is already making progress on its July 2023 deal with Roche to co-develop and commercialize zilebesiran, the former’s investigational RNAi therapeutic. The Cambridge biotech reported positive topline Phase II results Thursday for its partnered gene-silencing therapy to treat hypertension.
The trial data reinforces the potential for zilebesiran to offer “new possibilities in a field of medicine that has seen limited innovation in nearly 20 years,” said Simon Fox, program lead for the drug’s development.
The new multidisciplinary offering addresses industry need for more inclusive clinical trials and product development.
Biotech Beam Therapeutics has dosed the first patient in a Phase I/II study of its base-edited CAR-T therapy in relapsed or refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma.
